Skip to main content
Account

Table 6 Incidence of NEs occurring in ≥ 2% of patients with or without prior NEs

From: Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors

Patients with events

Patients with prior NEs (n = 66)

Patients without prior NEs (n = 123)

Any NE, n (%)

43 (65)

55 (45)

Dizziness

16 (24)

10 (8)

Tremor

12 (18)

21 (17)

Confusional state

10 (15)

4 (3)

Encephalopathy

6 (9)

4 (3)

Ataxia

6 (9)

3 (2)

Neurotoxicity

4 (6)

1 (1)

Lethargy

4 (6)

1 (1)

Convulsion

4 (6)

0

Aphasia

3 (5)

4 (3)

Dysarthria

3 (5)

3 (2)

Somnolence

2 (3)

7 (6)

Paresthesia

2 (3)

5 (4)

Disorientation

2 (3)

5 (4)

Mental status changes

2 (3)

5 (4)

Hypoesthesia

2 (3)

4 (3)

Memory impairment

2 (3)

1 (1)

Dysesthesia

2 (3)

1 (1)

Delirium

2 (3)

0

Reflexes abnormal

2 (3)

0

Amnesia

1 (2)

1 (1)

Depressed level of consciousness

1 (2)

0

Febrile delirium

1 (2)

0

Hemiparesis

1 (2)

1 (1)

Hyperreflexia

1 (2)

1 (1)

Facial nerve disorder

1 (2)

0

Leukoencephalopathy

1 (2)

0

Myoclonus

1 (2)

0

Postural dizziness

1 (2)

0

Restless legs syndrome

1 (2)

1 (1)

Bradyphrenia

0

2 (2)

Nervous system disorder

0

3 (2)

Cognitive disorder

0

3 (2)

Nystagmus

0

2 (2)

  1. NE neurologic event